APAC Asthma Therapeutics Market Analysed & Projected by GBI Research in Its Topical Report Published at MarketPublishers.com07 Apr 2016 • by Natalie Aster
LONDON – In the recent past, the Asia-Pacific asthma marketplace has seen the entrance of novel products, including Xolair (omalizumab), a recombinant DNA-derived humanized anti-IgE monoclonal antibody; Seretide (known as Advair in North America), a therapy with a combination of inhaled corticosteroids (ICS)/ long-acting beta-adrenoceptor agonists (LABAs); Relvar/Breo Ellipta, an ICS-LABA combination treatment; and Spiriva, a long-acting muscarinic antagonist (LAMA) tiotropium.
With more than 274 active pipeline molecules under development in different stages of clinical trials, the majority of the late-stage investigational drug candidates are being assessed, with enhanced dosing schemed and routes of administration as against currently marketed products.
Considering the clinical trials conducted since 2006, the highest failure rates of asthma molecules have been observed in phase III trials (46%), while the overall attrition rate for asthma in development was 78%.
Through to 2021, the region’s asthma therapeutics market is poised to surge from a value of USD 3.5 billion in 2014 to surpass the USD 5.6 billion mark by the end of the forecast period, posting a 7.2% CAGR. The considerable growth of the market will likely be primarily driven by the surging asthma prevalence and the adoption of more novel biologics.
Topical study “Asthma Therapeutics in Asia-Pacific Markets to 2021 - High Prevalence and Launch of Late-Stage Biologics will Drive the Market in Spite of Affordability Concerns” drawn up by GBI Research canvasses the Asia-Pacific asthma therapeutics marketplace. It provides true insights into the clinical framework of asthma; reviews the different products, therapeutic strategies, and firms that dominate the present-day landscape of marketed products as well as identifies the areas of unmet needs; analyses the essential pipeline trends in RoA, MoA, molecule type, and novelty. The study reveals the future risks and market opportunities; gives data on the molecules in late-stage clinical trials, which have displayed considerable therapeutic potential in asthma. A detailed comparison of the different usage patterns for asthma treatment, therapy costs per annum, and market growth forecasts is provided for China, Australia, India, Japan and South Korea. The report discusses the trends in licensing and co-development deals concerning asthma products and pinpoints the main strategic consolidations which have shaped the commercial landscape.
Asthma Therapeutics in Asia-Pacific Markets to 2021 - High Prevalence and Launch of Late-Stage Biologics will Drive the Market in Spite of Affordability Concerns
Published: March, 2016
Price: US$ 4,995.00
More reports created by the publisher can be found at GBI Research page.